Browse All

Current Filters

CLEAR FILTER x

TITLE

Feasibility of Measuring Functional Performance of FSHD Patients Using Wearable Sensors to Quantify Physical Activity

Author:Kools, Joost   Voermans, Nicol   Mul, Karlien   Jiang, John   Shoskes, Jennifer   Marshall, Kelly   Tarachandani, Anil   Figueredo, Joanita   Eggenspieler, Damien   

Session Name:S7: Outcome Measures and Observational Studies of Neuromuscular Diseases  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:S7.006  

Author Institution:Radboudumc, Nijmegen, Netherlands  Fulcrum Therapeutics, Cambridge, MA  UsinLife, LLC, Whitehouse Station, NJ  Sysnav SAS, Vernon, France  

Results from 96 Weeks Open-Label Extension of a Phase 2 Trial of Losmapimod in Subjects with FSHD: ReDUX4

Author:Wang, Leo   Han, Jay   Shoskes, Jennifer   Jiang, John   Tawil, Alrabi   

Session Name:S48: Therapeutics for Muscle Disease  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:S48.008  

Author Institution:University of Washington, Seattle, WA  UCI Medical Center, Orange, CA  Fulcrum Therapeutics, Cambridge, MA  University of Rochester Medical Center, Rochester, NY  

Safety and Tolerability of Losmapimod for the Treatment of FSHD

Author:Ramana, Vivekananda   Shoskes, Jennifer   

Session Name:P3: Neuromuscular Disease: Inherited Muscle Disorders 1  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:P3.001  

Author Institution:Fulcrum Therapeutics, Cambridge, MA  

Muscle Ultrasound in an Open-Label Study of Losmapimod in Subjects with FSHD1

Author:Kools, Joost   Voermans, Nicol   Mul, Karlien   Jiang, John   Shoskes, Jennifer   Marshall, Kelly   Karlsson, Markus   

Session Name:P5: Neuromuscular Disease: Inherited Muscle Disorders 2  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:P5.011  

Author Institution:Radboudumc, Nijmegen, Netherlands  Fulcrum Therapeutics, Cambridge, MA  AMRA Medical, Linköping, Sweden  

Design of REACH: Phase 3 Randomized, Double-Blind, Placebo-Controlled, 48-Week Study of the Efficacy and Safety of Losmapimod in FSHD

Author:Tawil, Alrabi   Han, Jay   Wang, Leo   Vissing, John   Statland, Jeffrey   Shoskes, Jennifer   Jiang, John   

Session Name:P6: Neuromuscular Disease: Inherited Muscle Disorders 3  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:P6.007  

Author Institution:University of Rochester Medical Center, Rochester, NY  UCI Medical Center, Orange, CA  University of Washington, Seattle, WA  University of Copenhagen, Copenhagen, Denmark  University of Kansas Medical Center, Kansas City, KS  Fulcrum Therapeutics, Cambridge, MA